|
1
|
Álvarez-Fernández C and Esteban-González
E: Current status of EGFR/ErbB inhibitors in non-small cell lung
carcinoma. Med Clin (Barc). 146(Suppl 1): 2–6. 2016.In Spanish.
View Article : Google Scholar
|
|
2
|
Juergens RA, Wrangle J, Vendetti FP,
Murphy SC, Zhao M, Coleman B, Sebree R, Rodgers K, Hooker CM,
Franco N, et al: Combination epigenetic therapy has efficacy in
patients with refractory advanced non-small cell lung cancer.
Cancer Discov. 1:598–607. 2011. View Article : Google Scholar
|
|
3
|
Martin M, Kettmann R and Dequiedt F: Class
IIa histone deacetylases: Conducting development and
differentiation. Int J Dev Biol. 53:291–301. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mottet D, Pirotte S, Lamour V, Hagedorn M,
Javerzat S, Bikfalvi A, Bellahcène A, Verdin E and Castronovo V:
HDAC4 represses p21 (WAF1/Cip1) expression in human cancer cells
through a Sp1-dependent, p53-independent mechanism. Oncogene.
28:243–256. 2009. View Article : Google Scholar
|
|
5
|
Feng GW, Dong LD, Shang WJ, Pang XL, Li
JF, Liu L and Wang Y: HDAC5 promotes cell proliferation in human
hepatocellular carcinoma by up-regulating Six1 expression. Eur Rev
Med Pharmacol Sci. 18:811–816. 2014.PubMed/NCBI
|
|
6
|
Cacan E: Histone deacetylase-1-mediated
suppression of FAS in chemoresistant ovarian cancer cells.
Anticancer Res. 36:2819–2826. 2016.PubMed/NCBI
|
|
7
|
Liu J, Gu J, Feng Z, Yang Y, Zhu N, Lu W
and Qi F: Both HDAC5 and HDAC6 are required for the proliferation
and metastasis of melanoma cells. J Transl Med. 14:72016.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wang L, Li H, Ren Y, Zou S, Fang W, Jiang
X, Jia L, Li M, Liu X, Yuan X, et al: Targeting HDAC with a novel
inhibitor effectively reverses paclitaxel resistance in non-small
cell lung cancer via multiple mechanisms. Cell Death Dis.
7:e20632016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang K, Zhang H, Zhou X, Tang WB, Xiao L,
Liu YH, Liu H, Peng YM, Sun L and Liu FY: miRNA589 regulates
epithelial-mesenchymal transition in human peritoneal mesothelial
cells. J Biomed Biotechnol. 2012:6730962012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Li W, Wang W, Ding M, Zheng X, Ma S and
Wang X: MiR-1244 sensitizes the resistance of non-small cell lung
cancer A549 cell to cisplatin. Cancer Cell Int. 16:302016.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang X, Jiang P, Shuai L, Chen K, Li Z,
Zhang Y, Jiang Y and Li X: miR-589-5p inhibits MAP3K8 and
suppresses CD90+ cancer stem cells in hepatocellular
carcinoma. J Exp Clin Cancer Res. 35:1762016. View Article : Google Scholar
|
|
12
|
Dávalos-Salas M, Furlan-Magaril M,
González-Buendía E, Valdes-Quezada C, Ayala-Ortega E and
Recillas-Targa F: Gain of DNA methylation is enhanced in the
absence of CTCF at the human retinoblastoma gene promoter. BMC
Cancer. 11:2322011. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Brzeziańska E, Dutkowska A and Antczak A:
The significance of epigenetic alterations in lung carcinogenesis.
Mol Biol Rep. 40:309–325. 2013. View Article : Google Scholar
|
|
14
|
Balgkouranidou I, Liloglou T and Lianidou
ES: Lung cancer epigenetics: Emerging biomarkers. Biomarkers Med.
7:49–58. 2013. View Article : Google Scholar
|
|
15
|
Miranda TB and Jones PA: DNA methylation:
The nuts and bolts of repression. J Cell Physiol. 213:384–390.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mehta A, Dobersch S, Romero-Olmedo AJ and
Barreto G: Epigenetics in lung cancer diagnosis and therapy. Cancer
Metastasis Rev. 34:229–241. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Patel K, Dickson J, Din S, Macleod K,
Jodrell D and Ramsahoye B: Targeting of 5-aza-2′-deoxycytidine
residues by chromatin-associated DNMT1 induces proteasomal
degradation of the free enzyme. Nucleic Acids Res. 38:4313–4324.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Damiani LA, Yingling CM, Leng S, Romo PE,
Nakamura J and Belinsky SA: Carcinogen-induced gene promoter
hypermethylation is mediated by DNMT1 and causal for transformation
of immortalized bronchial epithelial cells. Cancer Res.
68:9005–9014. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Forde PM, Brahmer JR and Kelly RJ: New
strategies in lung cancer: Epigenetic therapy for non-small cell
lung cancer. Clin Cancer Res. 20:2244–2248. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu ZH, Li J, Xia J, Jiang R, Zuo GW, Li
XP, Chen Y, Xiong W and Chen DL: Ginsenoside 20 (s)-Rh2 as potent
natural histone deacetylase inhibitors suppressing the growth of
human leukemia cells. Chem Biol Interact. 242:227–234. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhang J, Ng S, Wang J, Zhou J, Tan SH,
Yang N, Lin Q, Xia D and Shen HM: Histone deacetylase inhibitors
induce autophagy through FOXO1-dependent pathways. Autophagy.
11:629–642. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Jang SM, Kang EJ, Kim JW, Kim CH, An JH
and Choi KH: Transcription factor Sox4 is required for
PUMA-mediated apoptosis induced by histone deacetylase inhibitor,
TSA. Biochem Biophys Res Commun. 438:445–451. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Li A, Liu Z, Li M, Zhou S, Xu Y, Xiao Y
and Yang W: HDAC5, a potential therapeutic target and prognostic
biomarker, promotes proliferation, invasion and migration in human
breast cancer. Oncotarget. 7:37966–37978. 2016.PubMed/NCBI
|
|
24
|
Milde T, Oehme I, Korshunov A,
Kopp-Schneider A, Remke M, Northcott P, Deubzer HE, Lodrini M,
Taylor MD, von Deimling A, et al: HDAC5 and HDAC9 in
medulloblastoma: Novel markers for risk stratification and role in
tumor cell growth. Clin Cancer Res. 16:3240–3252. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Fan J, Lou B, Chen W, Zhang J, Lin S, Lv
FF and Chen Y: Downregulation of HDAC5 inhibits growth of human
hepatocellular carcinoma by induction of apoptosis and cell cycle
arrest. Tumour Biol. 35:11523–11532. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
He P, Liang J, Shao T, Guo Y, Hou Y and Li
Y: HDAC5 promotes colorectal cancer cell proliferation by
up-regulating DLL4 expression. Int J Clin Exp Med. 8:6510–6516.
2015.PubMed/NCBI
|
|
27
|
Gorgoulis VG, Zacharatos P, Mariatos G,
Kotsinas A, Bouda M, Kletsas D, Asimacopoulos PJ, Agnantis N,
Kittas C and Papavassiliou AG: Transcription factor E2F-1 acts as a
growth-promoting factor and is associated with adverse prognosis in
non-small cell lung carcinomas. J Pathol. 198:142–156. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Grossi F, Dal Bello MG, Salvi S, Puzone R,
Pfeffer U, Fontana V, Alama A, Rijavec E, Barletta G, Genova C, et
al: Expression of ribonucleotide reductase subunit-2 and
thymidylate synthase correlates with poor prognosis in patients
with resected stages I-III non-small cell lung cancer. Dis Markers.
2015:3026492015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Noro R, Miyanaga A, Minegishi Y, Okano T,
Seike M, Soeno C, Kataoka K, Matsuda K, Yoshimura A and Gemma A:
Histone deacetylase inhibitor enhances sensitivity of
non-small-cell lung cancer cells to 5-FU/S-1 via down-regulation of
thymidylate synthase expression and up-regulation of p21
(waf1/cip1) expression. Cancer Sci. 101:1424–1430. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tang YA, Lin RK, Tsai YT, Hsu HS, Yang YC,
Chen CY and Wang YC: MDM2 overexpression deregulates the
transcriptional control of RB/E2F leading to DNA methyltransferase
3A overexpression in lung cancer. Clin Cancer Res. 18:4325–4333.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li L and Wu D: miR-32 inhibits
proliferation, epithelial-mesenchymal transition, and metastasis by
targeting TWIST1 in non-small-cell lung cancer cells. Onco Targets
Ther. 9:1489–1498. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ávila-Moreno F, Armas-López L,
Álvarez-Moran AM, López-Bujanda Z, Ortiz-Quintero B,
Hidalgo-Miranda A, Urrea-Ramírez F, Rivera-Rosales RM,
Vázquez-Manríquez E, Peña-Mirabal E, et al: Overexpression of MEOX2
and TWIST1 is associated with H3K27me3 levels and determines lung
cancer chemoresistance and prognosis. PLoS One. 9:e1141042014.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Pérez-Ramírez C, Cañadas-Garre M, Molina
MA, Faus-Dáder MJ and Calleja-Hernández MA: PTEN and PI3K/AKT in
non-small-cell lung cancer. Pharmacogenomics. 16:1843–1862. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Li J, Yang S, Yan W, Yang J, Qin YJ, Lin
XL, Xie RY, Wang SC, Jin W, Gao F, et al: MicroRNA-19 triggers
epithelial-mesenchymal transition of lung cancer cells accompanied
by growth inhibition. Lab Invest. 95:1056–1070. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Yun F, Jia Y, Li X, Yuan L, Sun Q, Yu H,
Shi L and Yuan H: Clinicopathological significance of PTEN and
PI3K/AKT signal transduction pathway in non-small cell lung cancer.
Int J Clin Exp Pathol. 6:2112–2120. 2013.PubMed/NCBI
|
|
36
|
Liu Q, Sun Y, Zheng JM, Yan XL, Chen HM,
Chen JK and Huang HQ: Formononetin sensitizes glioma cells to
doxorubicin through preventing EMT via inhibition of histone
deacetylase 5. Int J Clin Exp Pathol. 8:6434–6441. 2015.PubMed/NCBI
|
|
37
|
Huang Y, Tan M, Gosink M, Wang KK and Sun
Y: Histone deacetylase 5 is not a p53 target gene, but its
overexpression inhibits tumor cell growth and induces apoptosis.
Cancer Res. 62:2913–2922. 2002.PubMed/NCBI
|
